 | Up a level |
Urwyler, Pascal; Leimbacher, Marina; Charitos, Panteleimon; Moser, Stephan; Heijnen, Ingmar A F M; Trendelenburg, Marten; Thoma, Reto; Sumer, Johannes; Camacho-Ortiz, Adrián; Bacci, Marcelo R; Huber, Lars C; Stüssi-Helbling, Melina; Albrich, Werner C; Sendi, Parham; Osthoff, Michael (2023). Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial. Frontiers in immunology, 14(1255292), p. 1255292. Frontiers Research Foundation 10.3389/fimmu.2023.1255292
Kahlert, Christian R; Persi, Raphael; Güsewell, Sabine; Egger, Thomas; Leal-Neto, Onicio B; Sumer, Johannes; Flury, Domenica; Brucher, Angela; Lemmenmeier, Eva; Möller, J Carsten; Rieder, Philip; Stocker, Reto; Vuichard-Gysin, Danielle; Wiggli, Benedikt; Albrich, Werner C; Babouee Flury, Baharak; Besold, Ulrike; Fehr, Jan; Kuster, Stefan P; McGeer, Allison; ... (2021). Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers - A multicentre cross-sectional study. Clinical microbiology and infection, 27(9), pp. 1336-1344. Elsevier 10.1016/j.cmi.2021.05.014
Urwyler, Pascal; Charitos, Panteleimon; Moser, Stephan; Heijnen, Ingmar A F M; Trendelenburg, Marten; Thoma, Reto; Sumer, Johannes; Camacho-Ortiz, Adrián; Bacci, Marcelo R; Huber, Lars C; Stüssi-Helbling, Melina; Albrich, Werner C; Sendi, Parham; Osthoff, Michael (2021). Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19). Trials, 22(1), p. 1. BioMed Central 10.1186/s13063-020-04976-x
